<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 4</label>
 <caption>
  <p>High-impact research opportunities identified to address key questions and reduce uncertainty in future iVDPV risk estimates</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Research opportunities</th>
    <th>Research questions</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="2">Retrospective analysis of global PID registries</td>
    <td>- What are the survival prospects of individuals in different PID categories in different income levels (particularly CVIDs) and how are they changing over time?</td>
   </tr>
   <tr>
    <td>- How does IVIG treatment affect PID survival?</td>
   </tr>
   <tr>
    <td rowspan="3">Expanded and longitudinal screening of PID patients for poliovirus (with reporting of IVIG treatment status for screened PID patients)</td>
    <td>- What fraction of patients with different PIDs (CVID, SCID, others) will develop prolonged and chronic excretion if infected with OPV?</td>
   </tr>
   <tr>
    <td>- How many prolonged and chronic excretors currently exist globally?</td>
   </tr>
   <tr>
    <td>- How does IVIG treatment affect the probability of developing a long-term infection if infected with OPV?</td>
   </tr>
   <tr>
    <td>Clinical trials with PAVDs involving long-term excretors</td>
    <td>- How effective are individual and combined PAVDs in clearing poliovirus infections?</td>
   </tr>
   <tr>
    <td rowspan="3">Systematic detailed reporting of timelines of events for all known long-term excretors</td>
    <td>- Does a PID patient who spontaneously recovered from a long-term infection develop sufficient immunity to prevent future long-term infections of the same or other serotypes?</td>
   </tr>
   <tr>
    <td>- How does IVIG treatment affect the probability of developing a long-term infection if infected with OPV?</td>
   </tr>
   <tr>
    <td>- What is the current survival and excretion status and the estimated time of infection, recovery (if applicable) and death (if applicable) for each known long-term excretor?</td>
   </tr>
   <tr>
    <td rowspan="2">Continued follow-up of all identified long term excretors (including after spontaneous recovery from infection )</td>
    <td>- Does a PID patient who spontaneously recovers from a long-term infection develop sufficient immunity to prevent future long-term infections of the same or other serotypes?</td>
   </tr>
   <tr>
    <td>- Do frequent concurrent enteric infections result in an increased probability of spontaneous recovery from long-term poliovirus infections?</td>
   </tr>
   <tr>
    <td rowspan="2">Intensification of searches for PID patients causing apparent iVDPVs isolated from the environment</td>
    <td>- Who are the sources of apparent iVDPVs isolated from the environment?</td>
   </tr>
   <tr>
    <td>- What are the bounds on current chronic excretor prevalence in countries that stopped using OPV?</td>
   </tr>
   <tr>
    <td rowspan="2">Expanded environmental surveillance for apparent iVDPVs</td>
    <td>- What are the bounds on current chronic excretor prevalence?</td>
   </tr>
   <tr>
    <td>- Can iVDPVs transmit widely?</td>
   </tr>
   <tr>
    <td>Modeling of iVDPV introductions into the general population after OPV cessation</td>
    <td>- What are the expected consequences of prolonged and chronic excretion beyond OPV cessation?</td>
   </tr>
   <tr>
    <td>Expanded stool sampling around known long-term excretors</td>
    <td>- Are iVDPVs as transmissible as cVDPVs and WPVs?</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
